Clinical Trial Update: CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigating Coramitug (NNC6019-0001) for heart failure due to transthyretin amyloid cardiomyopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Coramitug (coramitug)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Status: RECRUITING